Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Advanced Solid Tumors Clinical Trial

Official title:

Protocol RH-1-002: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Dose-escalation Study of RH-1 Administered as a 3-hour Intravenous Infusion in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00558727
• Other study ID #: RH-1-002
• Status: Terminated
• Phase: Phase 1
• First received: November 13, 2007
• Last updated: May 8, 2013
• Start date: November 2007
• Est. completion date: December 2008

Study information

• Verified date: May 2013
• Source: Spectrum Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).

Treatment will continue until a patient meets criteria for discontinuation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically proven advanced solid tumors or NHL, relapsed or refractory to conventional treatment, or for which no conventional therapy exists or is considered acceptable for the patient.

2. Tumor accessible for biopsy (required in expanded cohort of 24 patients only; optional in all other patients).

3. At least 18 years of age.

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

5. Life expectancy = 3 months.

6. Adequate hematological, hepatic, and renal function as defined by the following:

absolute neutrophil count (ANC) = 1.5 x 109/L, platelet count = 100 x 109/L, total bilirubin = 1.5 × the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 × ULN (AST/ALT = 5 × ULN if documented hepatic involvement), creatinine = 1.5 mg/dL or if serum creatinine is elevated then patient has a calculated creatinine clearance = 50 mL/min.

7. Toxic manifestations of previous treatment(s) have resolved, with the exceptions of = Grade 2 fatigue if stable for > 2 months, = Grade 2 alopecia and/or other Grade 1 toxicities, which in the opinion of the investigator should not exclude the patient (eg, palmar erythema; stable Grade 1 peripheral neuropathy).

8. Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Women who are postmenopausal for at least 1 year (defined as > 12 months since last menses) or are surgically sterilized do not require this test. Women of child-bearing potential and their male partners must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of RH-1. Adequate methods of contraception are double barrier methods (condoms with spermicidal jelly or foam, and diaphragm with spermicidal jelly or foam), oral, depot and injectable contraceptives, and intrauterine device (IUD). RH-1 should not be administered to women who are breast feeding.

9. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of RH-1.

10. Given written informed consent (IC).

Exclusion Criteria:

1. Active concurrent malignancy, with the exception of adequately treated carcinoma in situ of the cervix and/or basal or squamous cell carcinoma of the skin. If there is a history of prior malignancy, the patient must be disease-free for = 5 years.

2. Receipt of any investigational or conventional chemotherapy, targeted therapy, endocrine therapy, or immunotherapy within 4 weeks prior to study treatment or planned use during the course of the study. Hormonal therapy (gonadotropin-releasing hormone analog [leuprolide] for prostate cancer, somatostatin analog [octreotide] for carcinoid tumor, and anti-estrogens for breast cancer) will be allowed if the drug administration has been stable for = 4 weeks.

3. Use of any radiation therapy (RT) within 28 days prior to study treatment or planned use during the course of the study.

4. Requires therapeutic levels of anticoagulation therapy.

5. Failed treatment with a bone marrow transplant.

6. Active uncontrolled infection, underlying medical condition such as patients at poor medical risk because of non-malignant systemic disease, or other serious illness that would impair the ability of the patient to receive protocol treatment.

7. Known to be positive for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).

8. Symptomatic central nervous system (CNS) metastases or lesions for which treatment is required.

9. Major surgery within 4 weeks of planned start of treatment.

10. Previous exposure to RH-1.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Solid Tumors
• Lymphoma
• Lymphoma, Non-Hodgkin
• Non-Hodgkin's Lymphoma

Intervention

Drug:
• RH-1
1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.

Locations

Country	Name	City	State
United States	University of Colorado Health Science Center	Aurora	Colorado
United States	Hudson-Webber Cancer Research Center	Detroit	Michigan
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Cancer Therapy & Research Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of a 3-hour intravenous (IV) infusion of RH-1 administered once every 21 days.		Study duration	Yes
Secondary	To evaluate the safety and tolerability of 3-hour IV infusions of RH-1.		Study duration	Yes
Secondary	To determine the pharmacokinetic (PK) profile of 3-hour IV infusions of RH-1 administered at escalating doses.		Study duration	No
Secondary	To assess preliminary evidence of anti-cancer activity of RH-1.		Study duration	No
Secondary	To explore evidence of differential deoxyribonucleic acid (DNA) cross-linking and downstream phenotypic consequences of RH-1 exposure in peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), and tumor biopsies.		Study duration	No
Secondary	To explore the correlation and possible significance of germline polymorphisms in NAD(P)H:quinone oxidoreductase (NQO1) and DNA cross-linking as consequences of RH-1 exposure in PBMCs, CTCs, and tumor biopsies, as markers of anticancer activity.		Study duration	No